A.J. Loiacono was speaking at MedCity INVEST in late March in Chicago when an audience member requested him to address whether it is sustainable to have a system where after insurance a drug costs $150 for consumers whereas with GoodRx the same drug is $6. Loiacono took aim at PBMs but also didn't spare the federal government.
TSX Venture Exchange has a strong history of helping early stage health and life sciences companies raise patient capital for research and development purposes.
Through, Decision Path, Cardinal Health will offer cost and indication comparisons for oncology treatments, all within the EHR, for point-of-care use and help patients avoid financial toxicity — where they fall into debt and endure financial hardship because the treatments are so expensive.
Organ donation has long been a matter of demand outstripping supply, but Aurion Biotech aims to improve the supply part of the equation with a cell therapy. Aurion's technology turns a single donated cornea into treatments for up to 100 patients and the startup now has $120 million for clinical trials.
By Michael Schroeder Tuesday, April 12, 2022 6:06 PM
The infusion of cash brings IntelyCare's valuation to $1.1 billion, according to the company. Investment firm and asset manager Janus Henderson Investors led the Series C financing round.
The revenue cycle is incredibly complex due to shifting payer requirements, continuous regulatory compliance and coding updates, and emerging and evolving payment models. That complexity increases the administrative burden and drives up cost for providers.
By Gerald Gallagher and Doba Parushev Tuesday, April 12, 2022 2:01 PM
Primary care providers will function as the hub in a personalized care ecosystem, with the patient at the center. To accomplish this, they'll not only see patients in person but will engage them virtually as well, while also accessing more data to improve outcomes.
An FDA safety review has cleared Gilead Sciences to resume five clinical trials that were placed under a partial hold in January. The experimental Gilead drug, magrolimab, is part of a class of cancer immunotherapies that address a hot target for the field.
By Stephanie Baum Tuesday, April 12, 2022 10:18 AM
A recent webinar sponsored by Formlabs underscored the value of 3D printing from a clinical perspective and offered insight on how commercial and regulatory players are thinking about this space.
Congress must provide the Department of Health and Human Services the authority and flexibility to continue all federal telehealth waivers once the administration declares an end to the PHE.
No comments